third quarter of 2026
Filed Nov 5, 2026Natera Reports Third Quarter 2026 Financial Results
Third-quarter revenue increased 34.1%, test volume increased 22.3%, oncology test volume increased 60.9%, and the company raised its 2026 annual revenue guidance. Gross margin was slightly below the prior-year level and Natera continued to report an operating loss and net loss.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, three months ended September 30, 2026GAAP | $794M | – | 34.1% |
| Product revenues, three months ended September 30, 2026GAAP | $790.0M | – | – |
| Licensing and other revenues, three months ended September 30, 2026GAAP | $4M | – | – |
| Gross profit, three months ended September 30, 2026GAAP | $513.5M | – | – |
| Gross margin, three months ended September 30, 2026GAAP | 64.7% | – | – |
| Non-GAAP gross margin, three months ended September 30, 2026, excluding changes in estimates in revenue accrualsnon-GAAP | increased by approximately 1.4% sequentially | increased by approximately 1.4% sequentially | – |
| Change in estimates in revenue accruals, three months ended September 30, 2026GAAP | approximately $32.3 million | – | – |
| Gross-margin increase from changes in estimates, three months ended September 30, 2026GAAP | 1.5% | – | – |
| Tests processed, third quarter of 2026other | approximately 1,093,100 tests | – | 22.3% |
| Tests accessioned, third quarter of 2026other | approximately 1,080,300 tests | – | – |
| Tests reported, third quarter of 2026other | approximately 1,024,800 tests | – | 23.0% |
| Tests reported in laboratory, third quarter of 2026other | approximately 1,012,100 tests | – | – |
| Oncology tests processed, third quarter of 2026other | approximately 339,500 oncology tests | – | 60.9% |
| Clinical MRD oncology units, third quarter of 2026other | grew 32,700 units | grew 32,700 units | – |
| Cost of product revenues, three months ended September 30, 2026GAAP | $279.6M | – | – |
| Cost of licensing and other revenues, three months ended September 30, 2026GAAP | $871K | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | $242.4M | – | – |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | $333.7M | – | – |
| Total operating expenses, third quarter of 2026GAAP | $576.1M | – | 19.5% |
| Amortization of acquired intangible assets, third quarter of 2026GAAP | $5.7M | – | – |
| Total cost and expenses, three months ended September 30, 2026GAAP | $862.3M | – | – |
| Loss from operations, third quarter of 2026GAAP | $68.3M | – | – |
| Interest expense, three months ended September 30, 2026GAAP | $903K | – | – |
| Interest and other income, net, three months ended September 30, 2026GAAP | $9.61M | – | – |
| Loss before income taxes, three months ended September 30, 2026GAAP | $59.61M | – | – |
| Income tax expense, three months ended September 30, 2026GAAP | $299K | – | – |
| Net loss, third quarter of 2026GAAP | $59.9M | – | – |
| Net loss per share, basic and diluted, third quarter of 2026GAAP | ($0.42) per diluted share | – | – |
| Weighted-average shares used in computing basic and diluted net loss per share, third quarter of 2026GAAP | 144.1M | – | – |
| Total revenues, nine months ended September 30, 2026GAAP | $2.24B | – | – |
| Product revenues, nine months ended September 30, 2026GAAP | $2.23B | – | – |
| Licensing and other revenues, nine months ended September 30, 2026GAAP | $11.60M | – | – |
| Cost of product revenues, nine months ended September 30, 2026GAAP | $791.4M | – | – |
| Cost of licensing and other revenues, nine months ended September 30, 2026GAAP | $2.44M | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $681.2M | – | – |
| Selling, general and administrative expenses, nine months ended September 30, 2026GAAP | $988.8M | – | – |
| Amortization of acquired intangible assets, nine months ended September 30, 2026GAAP | $17.12M | – | – |
| Total cost and expenses, nine months ended September 30, 2026GAAP | $2.48B | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | $237.6M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | $212.0M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP | $(1.48) | – | – |
| Cash, cash equivalents and restricted cash, September 30, 2026GAAP | $1.10B | increased by approximately $5.7 million | – |
| Total outstanding debt balance, September 30, 2026GAAP | $80.3M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Product revenues, three months ended September 30, 2026The release cited an increase in volume and average selling price improvements for the increase in revenues. | $790.0M | – | – |
| Licensing and other revenues, three months ended September 30, 2026No separate driver was provided. | $4M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
2026 outlook
- Revenue$3.005 billion to $3.035 billion
- Gross marginapproximately 64% to 66%
- NoteSelling, general and administrative costs: approximately $1.225 billion to $1.300 billion
- NoteResearch and development costs: $825 million to $925 million
- NoteCash flow to be positive
What drove it
- Revenue growth was driven by an increase in volume and average selling price improvements.
- Oncology test volume increased 60.9% to approximately 339,500 oncology tests.
- Clinical MRD oncology units grew 32,700 units over the second quarter of 2026.
- The increase in operating expenses was primarily driven by headcount growth to support new product offerings and increases in clinical trial expenses.
- Gross profit reflected higher revenues and continued progress in reducing cost of revenues, offset by a smaller benefit from changes in estimates.
Concerns
- GAAP gross margin was 64.7%, compared to 64.9% in the third quarter of 2025.
- Natera reported a loss from operations of $68.3 million and a net loss of $59.9 million in the third quarter of 2026.
- The benefit to gross margin from changes in estimates was 1.5%, compared to 3.6% in the third quarter of 2025.
- Accounts receivable, net, was $471,354 (in thousands) at September 30, 2026, compared to $296,528 (in thousands) at December 31, 2025.
What to watch
- Execution against 2026 total revenue guidance of $3.005 billion to $3.035 billion.
- Whether gross margin remains within the approximately 64% to 66% 2026 outlook range.
- Progress toward the outlook for positive cash flow.
- Oncology test volume and clinical MRD oncology unit growth.
- Selling, general and administrative costs of approximately $1.225 billion to $1.300 billion and research and development costs of $825 million to $925 million.
Balance sheet and cash flow
- Cash, cash equivalents and restricted cash were $1,097.2 million at September 30, 2026, compared to $1,076.1 million as of December 31, 2025.
- Cash increased by approximately $5.7 million as of September 30, 2026 compared to June 30, 2026.
- Total outstanding debt balance was $80.3 million as of September 30, 2026, including accrued interest under the line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps.
- Accounts receivable, net, was $471,354 (in thousands) at September 30, 2026, compared to $296,528 (in thousands) at December 31, 2025.
- Inventory was $91,704 (in thousands) at September 30, 2026, compared to $68,443 (in thousands) at December 31, 2025.
Analysis
Natera delivered $794.0 million of third-quarter revenue, up 34.1% from $592.2 million in the third quarter of 2025. The release attributed the increase to higher volume and average selling price improvements. Tests processed increased 22.3% to approximately 1,093,100, while tests reported increased 23.0% to approximately 1,024,800. Oncology tests processed increased 60.9% to approximately 339,500, and clinical MRD oncology units grew 32,700 units over the second quarter of 2026.
Profitability improved in dollar terms but remained negative. Gross profit was $513.5 million, while GAAP gross margin was 64.7%, compared with 64.9% in the prior-year quarter. The company said gross profit benefited from higher revenue and cost-of-revenue reduction efforts, offset by a smaller benefit from changes in estimates. Changes in estimates increased gross margin by 1.5% in the quarter, versus 3.6% in the comparable 2025 period. Excluding revenue-accrual estimate changes, non-GAAP gross margin increased by approximately 1.4% sequentially.
Operating expenses were $576.1 million, up 19.5% from $482.0 million, primarily due to headcount supporting new product offerings and higher clinical trial expenses. Research and development expenses were $242,433 (in thousands), selling, general and administrative expenses were $333,656 (in thousands), and acquired-intangible amortization was $5.7 million. Loss from operations narrowed to $68.3 million from $97.6 million, while net loss narrowed to $59.9 million, or ($0.42) per diluted share, from $87.5 million, or ($0.64) per diluted share.
Liquidity was $1,097.2 million of cash, cash equivalents and restricted cash at September 30, 2026, an increase of approximately $5.7 million from June 30, 2026. Total outstanding debt was $80.3 million. Natera raised annual revenue guidance by $140 million at the midpoint to $3.005 billion to $3.035 billion and retained a gross-margin outlook of approximately 64% to 66%. The company also expects cash flow to be positive, with selling, general and administrative costs of approximately $1.225 billion to $1.300 billion and research and development costs of $825 million to $925 million.
Not in the filing
stated, not guessed- Prior-release outlook for formal actual-versus-prior-guidance comparison
- Operating cash flow for the reported quarter and nine-month period
- Free cash flow for the reported quarter and nine-month period
- Share repurchases
- Dividend declaration or payment
- Non-GAAP net income or loss
- Non-GAAP EPS
- Operating segment revenue disclosure
- Tax-rate guidance
- Quarterly GAAP total revenue prior-quarter comparison
- Quarterly GAAP gross-margin percentage change versus the prior year
- Named executive quotations
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.